Problem
Diagnostic testing can be fragmented, with patients struggling to compare prices, find reliable laboratories and understand reports. Curelo aims to simplify access to diagnostics and make preventive healthcare more accessible.
Product
Curelo is a digital diagnostics platform that connects patients with laboratory partners for test bookings and home sample collection. Its AI-powered Smart Reports and Dr. Curelo features help users better understand health information and diagnostic results.
Proof
The company reported more than 500,000 patients served and over 10 million health parameters tested in its July 2026 BioSpectrum India profile. Its official website also reports a network of 450+ laboratories across seven or more cities.
People
Curelo was founded by Dr. Arpit Jayswal, with Parth Jaiswal as Co-founder and CMO and Dr. Amit Arora as Co-founder and COO. The leadership team brings experience in diagnostics, healthcare operations, technology and consumer growth.
Purse
Curelo has reported raising ₹45 crore in total funding, according to its July 2026 BioSpectrum India profile. Earlier investors included cricketer Shreyas Iyer and IIMA Ventures, alongside family offices and other investors.
Plan
Curelo plans to expand into Tier 2 and Tier 3 cities while strengthening its AI-powered diagnostic intelligence platform. Its priorities include personalised health insights, improved report interpretation and wider adoption of preventive healthcare.
Why it matters:
Curelo is combining diagnostic access with AI-powered health insights to help patients move beyond test booking towards a better understanding of their health and preventive care needs.
FAST FACTS
|
Category
|
Details
|
|
Company
|
Curelo (Curis Healthtech Pvt. Ltd.)
|
|
HQ
|
Gurugram, Haryana
|
|
Founded
|
2022
|
|
Founders
|
Dr. Arpit Jayswal, Parth Jaiswal and Dr. Amit Arora
|
|
Core offering
|
Digital diagnostics and AI-powered health insights
|
|
Key features
|
Smart Reports, Dr. Curelo, home sample collection
|
|
Total funding
|
₹45 crore, as reported in July 2026
|
|
Reported reach
|
500,000+ patients served
|
|
Next
|
Tier 2 and Tier 3 expansion; strengthen AI-led personalised health insights
|
Disclaimer: This profile is based on publicly available information and company disclosures. Figures should be verified with the company before publication.
